These findings suggest that PVT1 is a potential therapeutic target for treating MM, AML, chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL) [316,331]. This evidence concerns the gene PVT1 and chronic myelogenous leukemia, BCR-ABL1 positive.